Orphanet Journal of Rare Diseases | Underrepresented Countries in Rare Disease Research: Morocco as a Case Study

Recommend:

This article highlights the importance of including underrepresented countries in rare disease research and uses Morocco as a case study to explore its unique contributions in terms of genetic diversity, untreated patient populations, and specific mutations, offering new perspectives and practical pathways for global collaboration in rare disease research.

 

Abstract

This article, titled Underrepresented Countries in Rare Disease Research: Morocco as a Case Study, published in the Orphanet Journal of Rare Diseases, reviews various European and global initiatives aimed at advancing rare disease research, and uses Morocco as a case study to explore its scientific and translational value in the context of genetic diversity, untreated patient populations, and unique mutations. The article emphasizes that integrating underrepresented countries into the European Rare Diseases Research Alliance (ERDREA) can promote equity and collaboration in global rare disease research, thereby improving diagnostic and therapeutic outcomes.

Background

Rare diseases (RDs) refer to conditions with extremely low prevalence in the general population, with approximately 5,000 to 7,000 identified to date, many of which are chronic, disabling, or genetic in nature. Due to the scarcity of patients, rare disease research faces challenges such as difficult diagnosis, limited treatment options, and fragmented data. To address these, Europe has launched several key initiatives, including EURORDIS, the European Reference Networks (ERNs), and the International Rare Diseases Research Consortium (IRDiRC), to integrate resources, standardize data, and foster international collaboration. Morocco, as an underrepresented country (UC), offers a unique resource for studying the genetic mechanisms and natural disease course of rare diseases due to its high rate of consanguinity, large untreated patient population, and unique genetic variants. Although Morocco currently faces challenges such as limited infrastructure and the absence of a national rare disease plan, recent developments like the establishment of metabolic platforms and related research have provided strong support for disease diagnosis and mechanistic studies. This article aims to explore Morocco’s scientific value within the ERDREA framework and its contributions to global rare disease research.

 

Assess the pathogenicity of gene variants, providing a reference for variant function analysis.

Learn More

 

Methods and Experimental Approach

This study uses Morocco as an example to analyze its unique assets in rare disease research, including genetic disease enrichment due to high consanguinity, a large untreated patient population, and unique or newly identified pathogenic variants. By reviewing Morocco’s research practices in the field of rare diseases over the past decade, the authors summarize the country’s potential value in observing natural disease courses, identifying therapeutic targets, accelerating clinical trials, and facilitating cross-border data integration. Additionally, the article discusses how regional collaboration and research platform development can enhance diagnostic and research capabilities in the absence of a national rare disease plan.

Key Findings and Perspectives

• Morocco’s high consanguinity rate leads to a concentrated population of rare disease patients, offering an ideal cohort for studying genotype-phenotype correlations and genetic mechanisms.
• A large untreated patient population aids in observing the natural progression of rare diseases and supports the development of precision diagnostics and novel therapies.
• Unique or newly identified pathogenic variants in Morocco provide international research consortia with distinct molecular targets and opportunities for drug repurposing.
• Including underrepresented countries in the ERDREA framework can enhance global equity, data integration, and innovation in rare disease therapies.

Implications and Future Directions

The article emphasizes that integrating underrepresented countries into the European Rare Diseases Research Alliance (ERDREA) not only contributes to scientific discovery but also promotes global equity and regional capacity building. In the future, with deeper international collaboration and standardized data, countries like Morocco are expected to play a more significant role in rare disease research, driving the development of new therapies and diagnostic tools. The establishment of national rare disease plans and reference laboratories is also highlighted as a key step for scientific advancement and patient care in these countries.

 

Enter a gene to explore its associated signaling pathways and known upstream/downstream molecules.

Learn More

 

Conclusion

This study systematically analyzes the unique scientific value of underrepresented countries in rare disease research, using Morocco as a representative case to illustrate its contributions in genetic diversity, untreated patient cohorts, and unique mutations. Integrating such countries into the European Rare Diseases Research Alliance (ERDREA) can enhance global equity and improve data integration and sharing in rare disease research. Morocco’s recent progress in metabolic platforms, next-generation sequencing, and patient cohort management provides a solid foundation for international research collaboration. Strengthening national-level rare disease strategies, establishing unified data standards, and promoting multi-party cooperation will further enhance research capacity and deliver more effective diagnostic and therapeutic solutions for rare disease patients worldwide.

 

Naima Fdil. The involvement of underrepresented countries in the European rare diseases research alliance: Morocco's assets. Orphanet Journal of Rare Diseases.